fda bpc 157 category 2 compounding list to Remove 12 Popular Peptides from the “Do Not Compound” FDA Peptide Update: Category 2
Description
This page notes that common side effects across nootropics can include headaches, nausea, insomnia, anxiety, and increased heart rate or blood pressure

This finding prompted the FDA to expand Wegovy's indication in March 2024 to include cardiovascular risk reduction
Kale J, Osterlund EJ, Andrews DW

Journal of pineal research
Fourteen samples with declared clomiphene were tested
